ST LOUIS/CAPE GIRARDEAU CCOP

圣路易斯-吉拉多角CCOP是由密苏里州东部和伊利诺伊州西部两个独立的两个州立医疗服务区的五家医院组成的联盟。来自包括伊利诺伊州奥尔顿在内的圣路易斯大都市区的调查人员隶属于该财团三家医院中的一家或多家，在过去15年里，他们在癌症治疗研究方案和最近的癌症控制研究方面进行了合作。吉拉多角的调查人员在过去的九年里一直与CCOP合作，并隶属于该市的两家医院。在接下来的五年里，我们预计NSABP和SWOG的癌症治疗研究方案每年至少获得80个学分，癌症控制和预防研究每年至少获得75个学分(新参与者和后续研究)。这些癌症控制积分将主要来自我们参与乳腺癌预防试验-1、前列腺癌预防试验-1和乳腺癌预防试验-2，前提是我们被选为一个站点。我们将继续利用过去15年开发的数据管理系统，为我们的研究基地西南肿瘤组和国家外科辅助乳房计划提供高质量的数据。总而言之，我们将继续我们过去15年在癌症治疗研究方面的出色表现，并扩大我们最近对癌症控制和预防试验的参与。研究人员和临床研究助理过去的经验和能力为社区临床肿瘤学计划的持续发展提供了坚实的基础。

The St. Louis-Cape Girardeau CCOP is a consortium of five hospitals in two separate bi-state health service areas in eastern Missouri and western Illinois. The Investigators from the St. Louis Metropolitan area, which includes Alton, Illinois, are affiliated with one or more of three hospitals in the consortium and have worked together for the past fifteen years in cancer treatment research protocols and more recently, in cancer control research studies. The Cape Girardeau Investigators have worked with CCOP for the past nine years and are affiliated with two hospitals in that city. During the next five years we expect to accrue at least eighty credits per year for cancer treatment research protocols of the NSABP and SWOG and at least seventy five credits (new participants and follow-up) per year for cancer control and prevention studies. These cancer control credits will be derived primarily from our participation in the Breast Cancer Prevention Trial-1, Prostate Cancer Prevention Trial-1 and the Breast Cancer Prevention Trial-2 provided we are chosen as a site. We will continue to provide high quality data to the Southwest Oncology Group and the National Surgical Adjuvant Breast Program which are our research bases, utilizing the data management system developed during the past fifteen years. In summary, we will continue our excellent performance of the last fifteen years in cancer treatment research studies and extend our more recent participation in cancer control and prevention trials as well. The past experience and capabilities of the Investigators and Clinical Research Associates provides a strong base for continuing development of this Community Clinical Oncology Program.